Skip to main content
. 2020 May 9;8(2):82. doi: 10.3390/pharmacy8020082

Table 2.

Absolute or relative contraindications to CHC based on hormone component [9,10].

Hormone Component Risks
Combined Hormonal Contraceptive (Estrogen + Progestin) Current breast cancer
Breastfeeding less than 21 days postpartum
Severe decompensated cirrhosis
Acute venous thromboembolism
High risk of recurrent venous thromboembolism
Major surgery with prolonged immobilization
Complicated diabetes
Migraine headache with aura
Uncontrolled hypertension
Current of history of ischemic heart disease
Known thrombogenic mutations (i.e., Factor V Leiden; prothrombin mutation; and protein S, protein C, and antithrombin deficiencies)
Multiple risk factors for atherosclerotic cardiovascular disease
Peripartum cardiomyopathy
Smokers greater than 35 years old
History of cerebrovascular accident
Systemic lupus erythematosus with positive antiphospholipid antibodies
Complicated valvular heart disease
Progestin-only Current breast cancer
Severe decompensated cirrhosis
Systemic lupus erythematosus with positive antiphospholipid antibodies